This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
ATC code
  • none
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass495.99 g/mol g·mol−1
3D model (JSmol)

Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class.[1][2] It is very potent and has an extremely long duration of action, lasting at least one week with a single dose.[3][4][5] It was developed by Janssen Pharmaceutica but was never marketed.

See also


  1. ^ De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica. 59 (5): 561–74. doi:10.1111/j.1600-0447.1979.tb00256.x. PMID 37697.
  2. ^ Knapen J, Bollen J, Brugmanns J, Rombaut N (1976). "[Treatment of chronic psychoses with oral clopimozide]". Acta Psychiatrica Belgica (in French). 76 (4): 644–57. PMID 798469.
  3. ^ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A (August 1975). "Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series". Arzneimittel-Forschung. 25 (8): 1287–94. PMID 1242360.
  4. ^ Floru L, Tegeler J (1978). "Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764)". Arzneimittel-Forschung. 28 (2): 341–4. PMID 25071.
  5. ^ Bobon J, Parent M, Toussaint C, Pinchard A (1976). "[Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)]". Acta Psychiatrica Belgica (in French). 76 (1): 138–43. PMID 970182.